Early antibodies for infants with HIV
Part of Infections clinical trials.
This study tests whether giving a special antibody treatment to babies living with HIV, shortly after birth, can help their immune system fight the virus better. It aims to improve their long-term health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be between 1 day and 12 months old.
- Your baby must have tested positive for HIV using a blood test.
- Your baby must weigh more than 2.5 kilograms (about 5.5 pounds).
- Your baby must not have had HIV treatment before, or only for 30 days or less.
- Your baby must be stable enough to be cared for at home, not in the hospital.
- You or your baby's legal guardian must be able to agree to the study and follow its rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody medication given as a shot to babies with HIV. It aims to help control the virus and may be an option for infants who are newly diagnosed or starting treatment.
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
This study tests if two lab-made antibodies can keep HIV under control when people temporarily stop their daily HIV medication. Participants will pause their antiretroviral therapy (ART) for a period and be closely monitored, with the goal of potentially finding a way to take a break from daily pills.
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.